Rocket Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Rocket Pharmaceuticals, Inc. (RCKT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.42M, a 31.67% decline year-over-year.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.49M, a 17.79% decline year-over-year.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $9.76M, a 13.24% decline year-over-year.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.86M, a 4.19% decline year-over-year.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.06M, a 15.62% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $43.92M, a 11.46% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $39.41M, a 27.08% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $31.01M, a 6.06% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.42M 10-Q · filed 2026-08-10 | $15.91M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $8.49M 10-Q · filed 2026-08-10 | |||||
| 2025-12-31 | $37.06M 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | $9.76M 10-Q · filed 2025-11-06 | $20.62M derived: sum of 2 quarters · filed 2026-08-10 | $30.95M derived: sum of 3 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $10.86M 10-Q · filed 2026-08-10 | $21.19M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $10.33M 10-Q · filed 2026-08-10 | |||||
| 2024-12-31 | $43.92M 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | $11.25M 10-Q · filed 2025-11-06 | $22.58M derived: sum of 2 quarters · filed 2025-11-06 | $32.83M derived: sum of 3 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $11.33M 10-Q · filed 2025-11-06 | $21.58M derived: sum of 2 quarters · filed 2025-11-06 | ||||
| 2024-03-31 | $10.25M 10-Q · filed 2025-11-06 | |||||
| 2023-12-31 | $39.41M 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | $10.32M 10-Q · filed 2024-11-07 | $20.56M derived: sum of 2 quarters · filed 2024-11-07 | $29.48M derived: sum of 3 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $10.24M 10-Q · filed 2024-11-07 | $19.16M derived: sum of 2 quarters · filed 2024-11-07 | ||||
| 2023-03-31 | $8.91M 10-Q · filed 2024-11-07 | |||||
| 2022-12-31 | $31.01M 10-K · filed 2025-02-27 | |||||
| 2022-09-30 | $7.68M 10-Q · filed 2023-11-07 | $15.05M derived: sum of 2 quarters · filed 2023-11-07 | $21.32M derived: sum of 3 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $7.37M 10-Q · filed 2023-11-07 | $13.64M derived: sum of 2 quarters · filed 2023-11-07 | ||||
| 2022-03-31 | $6.27M 10-Q · filed 2023-11-07 | |||||
| 2021-12-31 | $29.24M 10-K · filed 2024-02-27 | |||||
| 2021-09-30 | $6.99M 10-Q · filed 2022-11-04 | $14.30M derived: sum of 2 quarters · filed 2022-11-04 | $22.20M derived: sum of 3 quarters · filed 2022-11-04 | |||
| 2021-06-30 | $7.31M 10-Q · filed 2022-11-04 | $15.21M derived: sum of 2 quarters · filed 2022-11-04 | ||||
| 2021-03-31 | $7.90M 10-Q · filed 2022-11-04 | |||||
| 2020-12-31 | $18.57M 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | $4.05M 10-Q · filed 2021-11-05 | $8.54M derived: sum of 2 quarters · filed 2021-11-05 | $12.50M derived: sum of 3 quarters · filed 2021-11-05 | |||
| 2020-06-30 | $4.49M 10-Q · filed 2021-11-05 | $8.45M derived: sum of 2 quarters · filed 2021-11-05 | ||||
| 2020-03-31 | $3.96M 10-Q · filed 2021-11-05 | |||||
| 2019-12-31 | $13.37M 10-K · filed 2022-02-28 | |||||
| 2019-09-30 | $2.69M 10-Q · filed 2020-11-06 | $6.83M derived: sum of 2 quarters · filed 2020-11-06 | $10.01M derived: sum of 3 quarters · filed 2020-11-06 | $12.83M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $4.14M 10-Q · filed 2020-11-06 | $4.18M 10-Q · filed 2019-08-08 | $7.32M derived: sum of 2 quarters · filed 2020-11-06 | $10.14M derived: sum of 3 quarters · filed 2021-03-01 | $12.75M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $3.18M 10-Q · filed 2020-11-06 | $6.00M derived: sum of 2 quarters · filed 2021-03-01 | $8.61M derived: sum of 3 quarters · filed 2021-03-01 | $11.40M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.43M derived: sum of 2 quarters · filed 2021-03-01 | $8.22M derived: sum of 3 quarters · filed 2021-03-01 | $13.60M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $2.61M 10-Q · filed 2019-11-08 | $5.40M derived: sum of 2 quarters · filed 2019-11-08 | $10.78M 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $2.79M 10-Q · filed 2019-11-08 | $8.17M 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | $5.38M 10-Q · filed 2019-11-08 | |||||
| 2017-12-31 | $1.32M 10-K · filed 2019-03-08 | $4.04M 10-K · filed 2018-03-07 | ||||
| 2016-12-31 | $274.00K 10-K · filed 2019-03-08 | $2.91M 10-K · filed 2017-03-16 | ||||
| 2015-12-31 | $2.38M 10-K · filed 2017-03-16 | |||||
| 2014-12-31 | $177.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |